iCHOR Vascular. Clearing the path
As iCHOR Vascular finishes the limited market release (LMR) data and evaluation, we are transitioning into a planned early commercial funding round aimed at targeted revenue milestones combined with real-world clinical data across 3 FDA cleared devices uniquely designed to treat peripheral vascular occlusions across arteries, veins, and dialysis access.
Series A investors will anchor this early commercial round, leading the cap table into a growth phase with minimal dilution for existing stakeholders.
The investment case rests on a strong IP, next generation (post LMR) technology poised for commercialization, international market entry, and a pragmatic and disciplined approach to today’s commercialization processes.
iCHOR’s iSWEEP™ platform brings the gold-standard Fogarty surgical sweep into the endovascular suite; no capital equipment, no thrombolytics, no complex workflows. This simplicity unlocks adoption across hospitals, ASCs, and OBLs (office-based labs). iCHOR technology will drive faster procedure times, better outcomes, and improved economics in the Hospital, but equally supports the patient migration into the more efficient ASCs that enables many patients to be treated more proactively before issues become chronic ER admissions; ultimately leading to vastly improved outcomes.
This simple yet disruptive technology is focused on transforming underserved thrombectomy market segments; “thrombectomy gaps” in Peripheral Artery Disease (PAD), Deep Vein Thrombosis (DVT), and Dialysis Vascular Access while addressing the shortcomings of today’s therapies.
These segments represent billions in unmet need and a consolidating landscape ripe for disruption.
“iCHOR has built something rare: a capital-efficient, clinically validated platform entering commercialization at precisely the moment the market is consolidating. This round accelerates our path to strategic optionality; whether that’s a partnership, acquisition, or continued independent growth. We’re not waiting to be discovered; we’re building proof every day.”
Tim Blair, CEO
Learn More about iCHOR’s competitive funding positioning.
